

Allison Keshishian

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7174470/publications.pdf>

Version: 2024-02-01

7
papers

490
citations

1307594

7
h-index

1720034

7
g-index

7
all docs

7
docs citations

7
times ranked

779
citing authors

#	ARTICLE	IF	CITATIONS
1	Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients. <i>Stroke</i> , 2018, 49, 2933-2944.	2.0	246
2	Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in a real-world clinical practice. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1072-1082.	3.4	130
3	Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the United States Medicare population. <i>Current Medical Research and Opinion</i> , 2017, 33, 1595-1604.	1.9	55
4	Burden of major gastrointestinal bleeding among oral anticoagulant-treated non-valvular atrial fibrillation patients. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482199735.	3.2	19
5	Effectiveness and safety of direct oral anticoagulants compared to warfarin in treatment naïve non-valvular atrial fibrillation patients in the US Department of defense population. <i>BMC Cardiovascular Disorders</i> , 2019, 19, 142.	1.7	16
6	Health care costs and comorbidities for patients with inclusion body myositis. <i>Current Medical Research and Opinion</i> , 2018, 34, 1679-1685.	1.9	13
7	Non-persistence to Oral Anticoagulation Treatment in Patients with Non-valvular Atrial Fibrillation in the USA. <i>American Journal of Cardiovascular Drugs</i> , 2022, 22, 333-343.	2.2	11